LAM Extra for General Practicioners

[METFORMIN - BUT WHAT ELSE IS IN THE BOX?]

KISS Zsófia1, KIS János Tibor1

DECEMBER 15, 2011

LAM Extra for General Practicioners - 2011;3(05)

[Metformin is currentlly the most commonly prescribed oral antidiabetic drug for the treatment of patients with type 2 diabetes mellitus. Its administration is limited by the contraindications and the possible gastrointestinal side effects. In Hungary, metformin is currently available in numerous forms, among which the extended-release tablets are distinguished because of their tolerability. The authors summarise the most recent data about the favourable features of metformin, help clinicians to choose the appropriate preparation of metformin, and highlight the administration procedures that help to avoid gastrointestinal side effects.]

AFFILIATIONS

  1. Budai Irgalmasrendi Kórház Kht.

COMMENTS

0 comments

Further articles in this publication

LAM Extra for General Practicioners

[ECG ARTEFACTS]

TOMCSÁNYI János, BEZZEG Péter

[The recognition of ECG artefacts is becoming increasingly important for physicians working in the field of internal medicine. At the same time, however, very little information about artefacts is published in either articles or textbooks. The authors provide a summary of the generation, types and recognition of ECG artefacts. The aim of the article is to draw the attention of clinicians to the dangers of this increasingly common phenomenon. Unrecognised artefacts can often prompt further (unnecessary) investigations and may result in establishing wrong diagnosis as well as erroneous treatment decisions.]

LAM Extra for General Practicioners

[THE PLACE OF SULPHONYLUREA COMPOUNDS IN THE BLOOD GLUCOSE LOWERING THERAPY OF TYPE 2 DIABETES]

WINKLER Gábor

[The mechanism of blood glucose lowering action of sulphonylureas, their advantages and potencial risks are overviewd in the article. The author delineates the present place of the sulphonylurea group in the antihyperglycemic therapy of type 2 diabetes, listing possibilities of monotherapeutic as well as combined applications. It is emphasized that traditional insulin-secretagogue compounds have their place in the therapy of type 2 diabetes even beside of the new, incretin-type secretagogues.]

LAM Extra for General Practicioners

[ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH COPD - THE SIGNIFICANCE OF NEBIVOLOL]

FARSANG Csaba

[The occurrence of hypertension associated with chronic obstructive pulmonary disease (COPD) is increasing. Recognising COPD is important in order to choose the appropriate antihypertensive drugs. Antihypertensive drugs that can be used to treat patients with hypertension and COPD include diuretics, ACE-inhibitors, angiotensine receptor blockers (AT1 receptor antagonists) and calcium antagonists, as well as cardioselective beta blockers, as these drugs decrease total and cardiovascular mortality. Of these agents, the importance of the most cardioselective one, nebivolol should be stressed, as this drug has no clinically significant effect on parameters of respiratory function, and, through its additional effects (namely by increasing the synthesis of NO), it has a beneficial effect on COPD-related deterioration of respiratory functions, haemodynamic alterations (cor pulmonale) and local factors that participate in the respiratory inflammation and endothelial dysfunction.]

All articles in the issue

Related contents

Lege Artis Medicinae

[The role of metformin in the glucose-lowering therapy of patients with type 2 diabetes]

JERMENDY György

[Metformin is the oral antidiabetic drug of choice for patients with type 2 diabetes. Its effect is predominantly based on the reduction of insulin resistance by inhibiting hepatic glucose production. Metformin can be used as an initial oral antidiabetic drug at the start of, or in case of the failure of lifestyle modifications. Metformin is also used in dual or triple oral antidiabetic combinations, however, its use should not be suspended even if initiation of insulin therapy is indicated in patients with type 2 diabetes. Metformin does not increase bodyweight and the risk of hypoglycaemia, and recent data suggest that it decreases the risk of tumour development. Today, an extended- release (XR) formulation is also available besides the traditional one, which not only simplifies the treatment, but might also reduce the incidence of gastrointestinal adverse effects.]

Lege Artis Medicinae

[Metformin - but what else is in the box?]

KISS Zsófia, KIS János Tibor

[Metformin is currentlly the most commonly prescribed oral antidiabetic drug for the treatment of patients with type 2 diabetes mellitus. Its administration is limited by the contraindications and the possible gastrointestinal side effects. In Hungary, metformin is currently available in numerous forms, among which the extended-release tablets are distinguished because of their tolerability. The authors summarise the most recent data about the favourable features of metformin, help clinicians to choose the appropriate preparation of metformin, and highlight the administration procedures that help to avoid gastrointestinal side effects.]

Lege Artis Medicinae

[Several questions of medical treatments in polycystic ovary syndrome]

BAJNOK László

[Polycystic ovary syndrome is an endemic disease, thus its treatment is of great importance. In polycystic ovary syndrome, metformin decreases androgen levels, improves menstrual irregularity, hirsutism, ovulation ratio, and the efficiency of lifestyle interventions on visceral obesity, endothelial function and LDL-cholesterol level. It seems plausible to suppose that metformin decreases the incidence of diabetes in this group of patients. Metformin is superior to oral contraceptives/antiandrogens in respect of its effect on triglyceride level and insulin sensitivity, however, it is less effective in decreasing androgen levels, normalisation of the menstrual cycle and supposedly in the prevention of endometrial cancer. Metformin therapy improves fertility, however, when infertility is the main problem, it is not indicated as the primary treatment. In this case, ovulation induction, ovary drilling, as well as in vitro fertilization are warranted that can be supported by metformin therapy is some cases.]

Lege Artis Medicinae

[The role of the DPP-4 inhibitor sitagliptin in the therapy of type 2 diabetes, in light of the new guidelines]

HIDVÉGI Tibor

[Type 2 diabetes has become a global public health problem, threatening the economies of all nations, as a consequence of rapid urbanisation, changing eating habits, sedentary lifestyle and obesity. Asian populations tend to develop diabetes at younger ages and lower body mass index compared with Caucasians. The latest guidelines of the American Diabetes Association and the European Association for the Study of Diabetes recommend lifestyle interventions as the first step for patients with newly diagnosed type 2 diabetes. The widely used metformin remains one of the first-line drugs for type 2 diabetes. If monotherapy alone does not achieve or maintain the target HbA1c level, addition of a second oral agent is recommended as a second step. The highly selective dipetidyl peptidase-4 inhibitor sitagliptin and metformin are efficient and well tolerable. The complementary effects of sitagliptin and metformin lead to an efficient, safe and long-term improvement in glycaemic control.]

Lege Artis Medicinae

[THE ROLE AND METHODS OF IMPROVING INSULIN SENSITIVITY AND BETA-CELL FUNCTION IN TYPE 2 DIABETES]

GYIMESI András, TÁRNOK Enikő, TAYBANI Zoltán

[Increased knowledge on the pathogenesis of type 2 diabetes has considerably transformed the principles and practice of treatment. Insulin resistance and beta-cell dysfunction, the two main components of the pathogenesis both play a role in the conversion of normal glucose metabolism, through impaired glucose tolerance, into type 2 diabetes. Decreased insulin sensitivity, with or without beta-cell dysfunction, is present in the vast majority cases, therefore, its treatment is essential. Physical activity is known to improve insulin sensitivity. The primary action of the recommended first-line pharmacological agent metformin is the inhibition of hepatic glucose production but it also moderately stimulates muscle glucose uptake. Glitazones are insulin sensitizers that increase glucose uptake in muscle and adipose tissue and moderately decrease hepatic glucose production. Some evidence suggests that α-glucosidase inhibitors and also certain insulin secretagogues can improve the effect of insulin. Early detection of the pathologic state and an efficient treatment to improve both insulin sensitivity and beta-cell function are essential in order to slow the progression and prevent the development of complications in type 2 diabetes.]